TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06409208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth intervention (video and reminder SMSs)
Description: intervention includes educational video related to postnatal care and reminder SMSs related to postnatal visits, family planning adoption and exclusive breast feeding practice.
Study: NCT04890301

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CT guided biopsy for pulmonary nodule
Description: The technical process of the experimental group: ① design of puncture path, positioning and fixation of patients; ② puncture point positioning; ③ installation of navigation frame and template; ④ percutaneous lung biopsy guided by PT combined with CT.~The technical process of the active comparator group: ① planning puncture path, positioning and fixation of patients; ② positioning puncture point; ③ CT guided percutaneous lung biopsy.~The operation related information, complications and postoperative pathological results were collected.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CT guided biopsy for pulmonary nodule
Description: The technical process of the experimental group: ① design of puncture path, positioning and fixation of patients; ② puncture point positioning; ③ installation of navigation frame and template; ④ percutaneous lung biopsy guided by PT combined with CT.~The technical process of the active comparator group: ① planning puncture path, positioning and fixation of patients; ② positioning puncture point; ③ CT guided percutaneous lung biopsy.~The operation related information, complications and postoperative pathological results were collected.
Study: NCT05574608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD123-CAR-NK cells
Description: CD123-CAR-NK is an allogenic CD123-Targeted chimeric antigen receptor NK-cell (CAR-NK) therapy.
Study: NCT05679232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogel coating
Description: hydrogel coating applied to implant's surfaces during cementless hip revision arthroplasty

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: standard cementless hip revision arthroplasty
Study: NCT05252117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine Hydrochloride 40 MG/ML
Description: Analysis of uterovaginal plexus block with articain for intrauterine device placement
Study: NCT05728034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Injectable PrEP information
Description: Participants will be able to click on the links on the search results page (which reflect the five messaging strategies about injectable PrEP), visit those pages, and return to the main results page.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral PrEP information
Description: Participants will be able to click on the links on the search results page (which reflect the five messaging strategies about oral PrEP), visit those pages, and return to the main results page.
Study: NCT06053281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Daily Cholecalciferol 1000 IU in 24 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06658314

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental interventional group 1(Kinesiotaping)
Description: Kinesiotape will be applied by using two I-bands application technique:~Short band: to apply this ask the patient to move your arm behind her back as much as possible, then apply kinesiotape at the anterior glenohumeral joint.~Longer band: to apply this ask the patient to horizontal adduct her arm as much as possible, than apply kinesiotape targeting the posterior side of glenohumeral joint.~Apply both these band with paper-off stretch for 3-5 days or as depending upon skin sensitivity and tape adherence.~Kinesiotape will be applied once a week for total time period of 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental interventional group II (Graded exposure therapy)
Description: First week: gentle arm raises with 10 repetitions/day, slow and controlled stretch 25 to 50% force with 5 repetitions, passive internal and external rotations (with towel) with 5 repetitions each/day.~Second week: overhead arm raises (wall climbing) with 10 repetitions/day, pendulum exercises 10 repetitions/day, cross arm stretches 5 repetitions/day, active internal and external rotations with 5 repetitions each/day.~Third week: resistance exercises (initially with minimum weight or manual resistance), scapular squeezes 10 repetitions/day, gentle chest stretches 5 repetitions/day and gentle stretch with 75 to 100 % force 5 repetitions each/day.
Study: NCT06660862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: How darolutamide and hormone therapy affects the step count of older men who have prostate cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physician choice Androgen Deprivation (Hormone) Therapy
Description: How step count/physical activity affects certain quality of life changes these men experience such as differences in pain, mood, function, memory and fatigue
Study: NCT06662396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6552
Description: Oral Gelatin Coated Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Oral Extended-Release Capsule
Study: NCT06662253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Xa Guided Dosing of Low Molecular Weight Heparin
Description: Participants will receive Enoxaparin 0.5 mg/kg twice daily (rounded up or down to the nearest 10 mg) the initial starting dose. Dose adjustments will be made based on trough levels drawn between the 3rd and 4th dose. The target anti-Xa level range is between 0.1 and 0.2 IU/mL. If the patient is below the target range, then the next Enoxaparin dose will be increased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. If the patient is above the target range, then the next Enoxaparin dose will be decreased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. This dose will be maintained until hospital discharge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Dosing
Description: Participants will receive Enoxaparin dosed at the discretion of the most responsible physician (MRP). In cases of severe renal insufficiency (CrCl \&lt; 30mL/min\^:), the LMWH may dose reduced or changed to Heparin at the discretion of the MRP.
Study: NCT06659926

Intervention type: OTHER
Group type: OTHER
Intervention: 68Ga-PSMA-PET/CT scan
Description: 68Ga-PSMA-PET/CT scan at baseline and will be followed throughout the treatment with online patient reported outcome measure (PROM) questionnaires (Kaiku application) and blood sampling for circulating tumor DNA (ctDNA) analysis. At clinical progression, each patient will undergo a second 68Ga-PSMA-PET/CT to determine the location of disease progression and assess the value of 68Ga-PSMA-PET/CT imaging as a response measure
Study: NCT06658587

Intervention type: DIAGNOSTIC_TEST
Intervention: No interventions
Description: No interventions
Study: NCT06658223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with virtual reality
Description: The virtual reality program consisted of twelve sessions (2 per week for six weeks) of 10 min warm-up plus 15 minutes of exercise with the FitXR game (developed by FITAR LIMITED) on the Oculus Quest 2™ device. The warm-up consisted of moderate-intensity aerobic exercise on a cycle ergometer. The BORG CR-10 perceived exertion scale was used to determine this intensity. Subsequently, they continued with the FitXR game, starting with a 5-minute phase of muscular activation and global movements of their limbs. They performed eye-hand coordination exercises, hitting balls that came to the person at different speeds, and ended with muscle stretching and slow breathing. These exercises presented different difficulty levels and were adjusted to the person's condition. In the same way, as the game developed, it was possible to increase the level and thus increase its complexity.
Study: NCT06659588

Intervention type: OTHER
Intervention: Plasma, urine and stool collection
Description: During a consultation for follow-up, we will take an extra-volume during a blood sample taken as part of the care. We will also collect stool and urine.~There will be no biological collection for these samples. Organ biopsies carried out as part of the care (liver, kidney, digestive tract, spleen, lymph node) will also be studied as part of this research.

Intervention type: OTHER
Intervention: Plasma, urine and stool collection
Description: During a consultation for follow-up, we will take an extra-volume during a blood sample taken as part of the care. We will also collect stool and urine.~There will be no biological collection for these samples. Organ biopsies carried out as part of the care (liver, kidney, digestive tract, spleen, lymph node) will also be studied as part of this research.

Intervention type: OTHER
Intervention: Plasma, urine and stool collection
Description: During a consultation for follow-up, we will take an extra-volume during a blood sample taken as part of the care. We will also collect stool and urine.~There will be no biological collection for these samples. Organ biopsies carried out as part of the care (liver, kidney, digestive tract, spleen, lymph node) will also be studied as part of this research.

Intervention type: OTHER
Intervention: Plasma, urine and stool collection
Description: During a consultation for follow-up, we will take an extra-volume during a blood sample taken as part of the care. We will also collect stool and urine.~There will be no biological collection for these samples. Organ biopsies carried out as part of the care (liver, kidney, digestive tract, spleen, lymph node) will also be studied as part of this research.
Study: NCT06661252

Intervention type: DEVICE
Intervention: ABEL microsampler device
Description: The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.

Intervention type: DEVICE
Intervention: ABEL microsampler device
Description: The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.

Intervention type: DEVICE
Intervention: ABEL microsampler device
Description: The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.

Intervention type: DEVICE
Intervention: ABEL microsampler device
Description: The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.

Intervention type: DEVICE
Intervention: ABEL microsampler device
Description: The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.
Study: NCT06659042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered via Intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: administered via IV infusion
Study: NCT06661343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C4 Program
Description: The C4 intervention is a behavioral program designed to provide care coordination to address structural barriers to PrEP adherence among Black men who have sex with men (MSM). It includes personalized support services, focusing on healthcare access, mental health, and stigma reduction to promote consistent PrEP use. Participants will receive counseling sessions and follow-ups based on their individual needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C4 + 3MV Program
Description: This intervention combines the C4 care coordination with the 3MV behavioral program. The 3MV program focuses on behavior change, addressing self-efficacy, stigma, and promoting healthy practices. Through this combination, participants receive both structural and behavioral support to maximize their adherence to PrEP.
Study: NCT06658925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.
Description: Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.
Study: NCT06659120

Intervention type: DRUG
Intervention: Fremanezumab
Description: Initiation of anti-CGRP mAb (fremanezumab) treatment according to the Summary of Product Characteristics (SmPC) during clinical routine as a treatment of their physician (no study-specific intervention). This means that patients have to fulfil criteria for treatment with anti-CGRP mAbs in Switzerland, i.e. they have at least 8 days of migraine per month in the last three months.
Study: NCT04974827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg/3weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or Carboplatin
Description: Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
Study: NCT05365997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Default Nudge
Description: For patients whose clinician pods are randomized to the intervention arm, the care team pod will receive a message indicating that the patient is eligible for palliative care and that a default referral order has been pended for that patient. Clinicians will be given an opportunity to respond if they do not want their patient to be referred to palliative care. For clinicians who do not respond, after the allotted time, the Clinical Research Coordinator will reach out to the patient to introduce palliative care and ask if staff can schedule an appointment. For clinicians who respond no, the pended order will be removed and no patient contact by the research team will occur.
Study: NCT05434429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application
Description: Participants in the intervention group are able to access the intervention materials 5 days after enrollment. Two main self-guided intervention modules are available. Short-term self-guided intervention module include mainly audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation. Moreover, there based on breath relaxation exercises, craving management, and motivation to change. Long-term self-guided intervention module include CBT-based interventions, meditations, mindfulness, and journaling.
Study: NCT05252117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: Analysis of uterovaginal plexus block with mepivacaine for intrauterine device placement
Study: NCT06550258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equine-assisted therapy
Description: Hippotherapy is a therapeutic intervention applied by physiotherapists that aims to improve impaired body functions. Hippotherapy is a therapy in which the rider receives stimuli from the horse that stimulate the sensory, neuromotor and cognitive systems during riding and exercise on the back of a horse. Hippotherapy is effective on posture control, balance, gross motor functions and functional performance in children with cerebral palsy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Pediatric Physiotherapy
Description: In traditional pediatric physiotherapy, cushions of appropriate hardness were used for proprioceptive input. Stools of different heights were used for sitting, squatting, standing up by holding on and standing, Bobath balls and balance boards were used for balance reactions. Triangular and roll cushions of different hardness were used for weight transfer. Surfaces with different patterns were used for sensory input. The child's wishes and interests were taken into consideration in the selection of materials. The treatment was planned according to the activities that were difficult in daily life and the aim was to transfer the knowledge learned to daily life.
Study: NCT05642845

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin film-coated tablet 40 mg
Description: Atorvastatin is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of atorvastatin.

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin film-coated tablet 40 mg
Description: Atorvastatin is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of atorvastatin.

Intervention type: DRUG
Group type: OTHER
Intervention: Liprimar® film-coated tablet 40 mg
Description: Liprimar® is manufactured by Pfizer Pharmaceuticals LLC, Puerto Rico, LLC Polysan Scientific and Technological Pharmaceutical Firm; RU holder: Pfizer Inc, USA. Each tablet contains 40 mg of atorvastatin.

Intervention type: DRUG
Group type: OTHER
Intervention: Liprimar® film-coated tablet 40 mg
Description: Liprimar® is manufactured by Pfizer Pharmaceuticals LLC, Puerto Rico, LLC Polysan Scientific and Technological Pharmaceutical Firm; RU holder: Pfizer Inc, USA. Each tablet contains 40 mg of atorvastatin.
Study: NCT04868968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFV890
Description: 100 mg of DFV890 film coated tablets twice daily (b.i.d.). for 3 days starting in the morning of Day 1 and 100 mg of DFV890 in the morning on the fourth day.
Study: NCT06048965

Intervention type: OTHER
Intervention: No intervention to be performed
Description: No intervention to be performed. Anonymous survey only.
Study: NCT05575258

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 44-Day Diet Conventionally Sourced - YELLOW Diet
Description: Food for the conventional diet will be sourced from local grocery stores (non-organic produce) around Logan, UT, USA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 44-Day Diet Conventionally Sourced - YELLOW Diet
Description: Food for the conventional diet will be sourced from local grocery stores (non-organic produce) around Logan, UT, USA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 44-Day Diet Agro-Ecologically Sourced - GREEN Diet
Description: Food for the agro-ecological diet will be sourced predominantly from the Greenacres farm (Cincinnati, OH, USA) and a limited number of other retailers that sell select foods from agro-ecological producers (Seal the Seasons, General Mills, Pecan Shop, Sol Simple).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 44-Day Diet Agro-Ecologically Sourced - GREEN Diet
Description: Food for the agro-ecological diet will be sourced predominantly from the Greenacres farm (Cincinnati, OH, USA) and a limited number of other retailers that sell select foods from agro-ecological producers (Seal the Seasons, General Mills, Pecan Shop, Sol Simple).
Study: NCT04869215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EverVita Pro
Description: EverVita Pro is composed of barley and corn, grown and mechanically processed in Europe, with non-GMO grains.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control bread
Description: Bread baked with normal Bakers flour
Study: NCT06028321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 Group 1 Regime A (ACM-001.1)
Description: Drug: ACM-001.1 immediate release tablets for oral use and matching placebo, and pindolol tablets for oral use.~Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 Group 1 Regime A (ACM-001.1)
Description: Drug: ACM-001.1 immediate release tablets for oral use and matching placebo, and pindolol tablets for oral use.~Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 Group 2 Regimen C (Pindolol)
Description: Drug: Pindolol tablets for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 Group D (Pindolol)
Description: Drug: Pindolol tablets for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 Group E (ACM-001.1)
Description: Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
Study: NCT04939402

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serological testing
Description: Antibody testing for Sars-CoV-2 specific antibodies in blood + T cell immunity
Study: NCT06558565

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stromal vascular fraction or platelet rich plasma
Description: stromal vascular fraction will be injected in one half of the scalp \& PRP will be injected in the other half
Study: NCT06028321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 Group F (ACM-001.1 )
Description: Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 Group G (ACM-001.1)
Description: Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 Group 1 Regimen B (Pindolol)
Description: Drug: pindolol tablets for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 Group 1 Regimen B (Pindolol)
Description: Drug: pindolol tablets for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Part 1 Group 1 Regimen A (Placebo)
Description: Placebo for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Part 1 Group 1 Regimen A (Placebo)
Description: Placebo for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
Study: NCT06028321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Part 2 Group E (Placebo)
Description: Placebo for oral use. Subjects were dosed over a four day treatment period twice daily.~Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
Study: NCT06204510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: complex decongestive therapy
Description: This application consists of manual lymph drainage, skin care, compression bandage and exercises. This phase will continue for 3 weeks, 5 days a week.